Combined Buprenorphine and Behavioral Treatment With and Without Contingent Reinforcement on Opioid and Cocaine Abstinence. - 22 - Full Text View

Combined Buprenorphine and Behavioral Treatment With and Without Contingent Reinforcement on Opioid and Cocaine Abstinence. - 22

This study has been completed.

Sponsored by:	National Institute on Drug Abuse (NIDA)
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000240

Purpose

The purpose of this study is to test combined buprenorphine and behavioral treatment with and without contingent reinforcement on opioid and cocaine abstinence.

Condition	Intervention	Phase
Cocaine-Related Disorders Opioid-Related Disorders	Drug: Buprenorphine	Phase II

Drug Information available for:

Buprenorphine Buprenorphine hydrochloride 8-Azabicyclo(3.2.1)octane-2-carboxylic acid, 3-(benzoyloxy)-8-methyl-, methyl ester, (1R-(exo,exo))- Cocaine hydrochloride

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Open Label

Official Title:	Combined Buprenorphine and Behavioral Treatment Without Contingent Reinforcement

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Drug use
Retention
Weeks abstinent
Weeks continuous abstinence
Overall treatment outcome
Opioid dependence and psychiatric status

Estimated Enrollment:	0
Study Start Date:	April 1999

Eligibility

Ages Eligible for Study:	23 Years to 47 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000240

Locations


United States, Vermont
	Treatment Research Center
	Burlington, Vermont, United States, 05401

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

Investigators


Principal Investigator:	Warren Bickel, Ph.D.	University of Vermont

More Information

Study ID Numbers:	NIDA-06969-22, R01-06969-22
First Received:	September 20, 1999
Last Updated:	August 16, 2005
ClinicalTrials.gov Identifier:	NCT00000240
Health Authority:	United States: Federal Government

Study placed in the following topic categories:

Cocaine-Related Disorders

Buprenorphine

Mental Disorders

Substance-Related Disorders

Disorders of Environmental Origin

Cocaine

Opioid-Related Disorders

Additional relevant MeSH terms:

Disease

Physiological Effects of Drugs

Narcotic Antagonists

Central Nervous System Depressants

Narcotics

Pharmacologic Actions

Pathologic Processes

Sensory System Agents

Therapeutic Uses

Analgesics

Peripheral Nervous System Agents

Central Nervous System Agents

Analgesics, Opioid

ClinicalTrials.gov processed this record on October 29, 2008